Urogen Pharma EBIT per Share
The EBIT per Share of Urogen Pharma (URGN) as of Oct 31, 2026 is -2.55 USD. In the previous year, EBIT per Share was -2.06 USD — a change of 23.91% (lower).
Get this data via API
Financial Data API
EBIT per Share
-2.55USD
YoY
23.91%
Last updated:
The Urogen Pharma EBIT per Share history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | 11.26USD | +28.23% |
| est | 8.78USD | +35.09% |
| est | 6.50USD | +63.56% |
| est | 3.97USD | +2,267.43% |
| est | 0.17USD | -106.58% |
| -2.55USD | +23.91% | |
| -2.06USD | +19.89% | |
| -1.72USD | -49.86% | |
| -3.42USD | -16.79% | |
| -4.11USD | -28.11% | |
| -5.72USD | +10.60% | |
| -5.17USD | +8.69% | |
| -4.76USD | +224.84% | |
| -1.47USD | -2,112.94% | |
| 0.07USD | -101.35% | |
| -5.39USD | +184.05% | |
| -1.90USD | +18.61% | |
| -1.60USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Urogen Pharma Stock analysis
Frequently Asked Questions about Urogen Pharma stock
EBIT per Share of Urogen Pharma is -2.55 USD in 2025.
EBIT per Share of Urogen Pharma changed from -2.06 USD to -2.55 USD, representing a 23.91% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Urogen Pharma since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Urogen Pharma
All Key Metrics — Urogen Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth